At the STI & HIV 2025 World Congress, Assembly Biosciences, Inc. presented Phase 1a clinical data for its herpes simplex virus helicase-primase inhibitor candidates ABI-5366 and ABI-1179. These candidates could potentially provide a once weekly or once monthly oral dosing option for recurrent genital herpes, reducing the treatment burden. The company also highlighted preclinical data and U.S. genital herpes prevalence and treatment patterns. Interim proof-of-concept Phase 1b data is expected in fall 2025 for both candidates. The presentations showcased the safety and pharmacokinetic profiles of the candidates, supporting their progression to Phase 1b evaluation.

Read more at GlobeNewswire: Assembly Biosciences Presents Data Highlighting Recurrent